Fighting Renal Diseases in Poor Countries: Building a Global Fund with the Help of the Pharmaceutical Industry

Journal of the American Society of Nephrology

Volumn 15, Issue 3, 2004, Pages 704-707

  Schieppati, Arrigo ^a,b   Remuzzi, Giuseppe ^a,b  

^a MARIO NEGRI INST PHARMACOL RES   (Italy)

^b OSPEDALI RIUNITI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IRBESARTAN; LOSARTAN; PLACEBO; RAMIPRIL;

AFRICAN AMERICAN; BUDGET; CANADA; DEVELOPING COUNTRY; DIABETES CONTROL; DIABETIC NEPHROPATHY; DRUG INDUSTRY; EUROPEAN UNION; FINANCIAL MANAGEMENT; GLOMERULUS FILTRATION RATE; HEALTH CARE COST; HEMODIALYSIS; HYPERTENSION; INCIDENCE; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY DISEASE; KIDNEY TRANSPLANTATION; LIFESTYLE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT CARE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; UNITED STATES; WORLD HEALTH ORGANIZATION;

EID: 1542318960     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ASN.0000113317.64112.99     Document Type: Review

References (28)

1. Lysaght MJ: Maintenance dialysis population dynamics: Current trends and long-term implications. J Am Soc Nephrol 13: S37-S40, 2002
2. Xue JL, Ma JZ, Louis TA, Collins AJ: Forecast of the number of patients with end-stage renal disease in the United States to the year 2010. J Am Soc Nephrol 12: 2753-2758, 2001
3. US Renal Data System: Excerpts from the USRDS 2001 Annual Data Report: Atlas of end-stage renal disease in the United States. Am J Kidney Dis 38[Suppl 3]: S1-S248, 2001
4. Jones CA, McQuillan GM, Kusek JW, Eberhardt MS, Herman WH, Coresh J, Salive M, Jones CP, Agodoa LY: Serum creatinine levels in the US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 32: 992-999, 1998
5. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP: Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 322: 1561-1566, 1990
6. Ruggenenti P, Schieppati A, Remuzzi G: Progression, remission, regression of chronic renal diseases. Lancet 357: 1601-1608, 2001
7. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 329: 1456-1462, 1993
8. Brenner BM: Retarding the progression of renal disease. Kidney Int 64: 370-378, 2003
9. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia): Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 349: 1857-1863, 1997
10. Jafar TH, Schmid CH, Landa M, Giatras I, Toto R, Remuzzi G, Maschio G, Brenner BM, Kamper A, Zucchelli P, Becker G, Himmelmann A, Bannister K, Landais P, Shahinfar S, de Jong PE, de Zeeuw D, Lau J, Levey AS: Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med 135: 73-87, 2001
11. Wright JT Jr, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, Cheek D, Douglas-Baltimore JG, Gassman J, Glassock R, Hebert L, Jamerson K, Lewis J, Phillips RA, Toto RD, Middleton JP, Rostand SG; African American Study of Kidney Disease and Hypertension Study Group: Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: Results from the AASK trial. JAMA 288: 2421-2431, 2002
12. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S; RENAAL Study Investigators: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Eng J Med 345: 861-869, 2001
13. Lewis EJ, Hunsicker LG, Clarke WR, Bert T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I; Collaborative Study Group: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345: 851-860, 2001
14. Usami T, Kato N, Nakao N, Fukuda M, Takeuchi O, Kamiya Y, Yoshida A, Kimura G: Shift of regional distribution of end-stage renal disease in Japan after the appearance of angiotensin-converting enzyme inhibitors. American Society of Nephrology Renal Week 2003, San Diego. Available at: www.abstracts2view. com/asn/sessionindex.php
15. Gerth WC, Remuzzi G, Viberti GC, Hannedouche T, Martinez-Castelao A, Shahinfar S, Carides GW, Brenner B: Losartan reduces the burden and cost of ESRD: Public health implications of the RENAAL study for the European Union. Kidney Int 62: 568-572, 2002
16. Rutkowski B, Ciocalteu A, Djukanovic L, Kiss I, Kovac A, Krivoshiev S, Kveder R, Polenakovic M, Puretic Z, Stanaityte M, Tareyeva I, Teplan V, Zavitz J: Evolution of renal replacement therapy in Central and Eastern Europe 7 years after political and economical liberation. Central and Eastern Europe Advisory Board in Chronic Renal Failure. Nephrol Dial Transplant 13: 860-864, 1998
17. Berthoux F, Jones E, Gellert R, Mendel S, Saker L, Briggs D: Epidemiological data of treated end-stage renal failure in the European Union (EU) during the year 1995: Report of the European Renal Association Registry and the National Registries. Nephrol Dial Transplant 14: 2332-2342, 1999
18. Thomas MC, Cooper ME, Shaninfar S, Brenner BM: Dialysis delayed is death prevented: A clinical perspective on the RENAAL study. Kidney Int 63: 1577-1579, 2003
19. Mani MK: Clinical and epidemiological programme on renal disease. Nephrol Dial Transplant 14: 1807-1808, 1999
20. Plata R, Silva C, Yahuita J, Perez L, Schieppati A, Remuzzi G: The first clinical epidemiological programme on renal disease in Bolivia: A model for prevention and early diagnosis of renal diseases in developing countries. Nephrol Dial Transplant 13: 3034-3036, 1998
21. Hoy WE, Baker PRA, Kelly AM, Wang Z: Reducing premature death and renal failure in Australian Aborigines: Results of a community-based cardiovascular and renal-protective program. Med J Aus 172: 473-478, 2000
22. Henry D, Lexchin J: The pharmaceutical industry as a medicine provider. Lancet 369: 1590-1595, 2002
23. Guilloux A, Moon S: Hidden price tag: Disease-specific drug donations. Cost and alternatives. MSF/DND Working group. February 1, 2001. Available at: www.accessmed-msf.orglupload/ReportsandPublications/2092002185426/4-3.pdf
24. Angell M: The pharmaceutical industry. To whom is it accountable? N Engl J Med 342: 1902-1904, 2000
25. Gerth J, Stolberg SG: Drugs makers reap profits on tax-backed research. New York Times April 23: 1, 2000
26. Tu K, Mamdani MM, Jacka RM, Forde NJ, Rothwell DM, Tu JV: The striking effect of the Heart Outcomes Prevention Evaluation (HOPE) on ramipril prescribing in Ontario. CMAJ 168: 553-557, 2003
27. IMS Health World Review: The global pharmaceutical market in 2000-North America sets the pace. Available at: www.imsglobal.com/insight/news_story/0103/news_story_010314.htm. Accessed May 27, 2003
28. Tan DHS, Upshur REG, Ford N: Global plagues and the Global Fund: Challenges in the fight against HIV, TB and malaria. BMC International Health and Human Rights 2003: 3:2. Available at: www.biomedcentral.com/1472-69SX/3/2. Accessed on October 23, 2003